Idiopathic nephrotic syndrome (new-onset in children)
Conditions
Interventions
Rituximab group (RTX group):None
Conventional corticosteroid therapy group (CS group):None
Sponsors
Children's Hospital,Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
2 Years to 17 Years
Inclusion criteria
Inclusion criteria: 1.Age 2-17 years; 2.First clinical diagnosis of idiopathic nephrotic syndrome; 3.Initial treatment with rituximab monotherapy or oral prednisone/prednisolone; 4.Normal glomerular function: eGFR >=90 ml/min/1.73m^2; 5.Complete clinical data;
Exclusion criteria
Exclusion criteria: 1.Secondary nephrotic syndrome (e.g., systemic lupus erythematosus, Henoch-Schönlein purpura, IgA nephropathy, hepatitis B-associated glomerulonephritis, membranoproliferative glomerulonephritis, membranous nephropathy, amyloidosis, etc. 2.Congenital or infantile nephrotic syndrome (age of onset <1 year); 3.Family history of nephrotic syndrome, chronic glomerulonephritis, uremia or other kidney diseases, or confirmed monogenic mutations (WT1, NPHS2, LAMB2, PLCE1, etc.) by genetic testing; 4.Received corticosteroids or other immunosuppressants (cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil, Tripterygium wilfordii, etc.) for other diseases within 3 months before disease onset;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse-free survival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of frequent relapses;Number of relapses;Adverse events; | — |
Countries
China
Contacts
Public ContactQiuyu Li
Children's Hospital,Zhejiang University School of Medicine
Outcome results
None listed